|
Monopar Therapeutics Inc. (MNPR) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Monopar Therapeutics Inc. (MNPR) Bundle
Vereinfachen Sie die Bewertung von Monopar Therapeutics Inc. (MNPR) mit diesem anpassbaren DCF -Taschenrechner! Mit Real Monopar Therapeutics Inc. (MNPR) -Fonds und einstellbaren Prognoseeingaben können Sie Szenarien testen und Monopar Therapeutics Inc. (MNPR) in Minuten fairen Wert aufdecken.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | .0 | .0 | .0 | .0 | .4 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | 4.3 | 6.5 | 9.1 | 10.5 | 8.8 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -4.3 | -6.5 | -9.1 | -10.5 | -8.4 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 13.2 | 16.7 | 20.3 | 13.1 | 7.3 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | .7 | 1.2 | 1.6 | 3.1 | 1.8 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -4.2 | -6.4 | -9.1 | -10.5 | -8.4 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | .8 | .5 | .4 | 1.6 | -.9 | -1.8 | .0 | .0 | .0 | .0 |
| WACC, % | 10.24 | 10.24 | 10.24 | 10.24 | 10.24 | 10.24 | 10.24 | 10.24 | 10.24 | 10.24 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -1.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -2 | |||||||||
| Net Debt | -7 | |||||||||
| Equity Value | 6 | |||||||||
| Diluted Shares Outstanding, MM | 15 | |||||||||
| Equity Value Per Share | 0.39 |
What You Will Get
- Real MNPR Financial Data: Pre-filled with Monopar Therapeutics Inc.’s historical and projected data for precise analysis.
- Fully Editable Template: Modify key inputs like revenue growth, WACC, and EBITDA % with ease.
- Automatic Calculations: See Monopar Therapeutics Inc.’s intrinsic value update instantly based on your changes.
- Professional Valuation Tool: Designed for investors, analysts, and consultants seeking accurate DCF results.
- User-Friendly Design: Simple structure and clear instructions for all experience levels.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Monopar Therapeutics Inc. (MNPR).
- WACC Calculator: Comes with a pre-built Weighted Average Cost of Capital sheet that allows for customizable inputs.
- Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for Monopar Therapeutics Inc. (MNPR).
- Interactive Dashboard and Charts: Visual representations summarize essential valuation metrics for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Monopar Therapeutics Inc.'s pre-filled financial data and forecasts.
- Step 3: Modify critical inputs like revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Watch the DCF model update instantly as you tweak assumptions.
- Step 5: Analyze the outputs and use the results for investment decisions.
Why Choose This Calculator for Monopar Therapeutics Inc. (MNPR)?
- User-Friendly Interface: Perfectly crafted for both novices and seasoned professionals.
- Customizable Inputs: Effortlessly adjust parameters to suit your financial analysis.
- Real-Time Valuation: Instantly view changes in Monopar’s valuation as you modify inputs.
- Preloaded Data: Comes with Monopar’s actual financial statistics for swift evaluations.
- Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.
Who Should Use Monopar Therapeutics Inc. (MNPR)?
- Investors: Gain insights into innovative therapeutics with a focus on oncology and rare diseases.
- Pharmaceutical Analysts: Streamline evaluations with access to comprehensive clinical trial data and market analysis.
- Healthcare Consultants: Easily tailor reports and presentations to showcase Monopar's strategic initiatives.
- Biotech Enthusiasts: Enhance your knowledge of drug development processes and the biotech landscape.
- Educators and Students: Utilize it as a resource for case studies in pharmaceutical and biotechnology courses.
What the Template Contains
- Pre-Filled DCF Model: Monopar Therapeutics Inc.’s (MNPR) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital specific to Monopar Therapeutics Inc. (MNPR).
- Financial Ratios: Evaluate Monopar Therapeutics Inc.’s (MNPR) profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios for Monopar Therapeutics Inc. (MNPR).
- Financial Statements: Annual and quarterly reports for Monopar Therapeutics Inc. (MNPR) to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results for Monopar Therapeutics Inc. (MNPR).
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.